Ventus Medical, a company that specializes in treating sleep disordered breathing ranging from snoring to obstructive sleep apnea, has developed Theravent Snore Therapy, which received FDA clearance in June using a new class of snoring therapy.
The therapy, exclusively available online to consumers at www.theraventsnoring.com (no prescription required), is for people whose snoring affects sleep quality for themselves or their bed partners.
“Snoring has always been a laughable problem in society, but doctors now know that it’s related to other health risks in addition to being a nuisance to bed partners, and should be treated,” said Peter Wyles, president and CEO of Ventus Medical. “Theravent was born out of our extensive research and experiences in treating obstructive sleep apnea with Provent Sleep Apnea Therapy. We’re confident that this new, single-use device will greatly benefit the millions of snorers and their bed partners whose lives have been adversely impacted by snoring.”
Theravent uses the same MicroValve technology first introduced in Ventus Medical’s prescription-only Provent Sleep Apnea Therapy. Theravent utilizes this technology to increase pressure in the upper airway when a user exhales, reducing or eliminating snoring. Clinical studies at multiple US centers demonstrated that successful Theravent users reduced snoring by an average of 76%, as measured using a decibel meter, according to Ventus. The company emphasizes that Theravent is not intended to treat obstructive sleep apnea.